-transparent.png){kind=logo}
Both cell mediated immunity and humoral immunity was assessed in 16 patients of hydatidiform mole and 6 patients of choriocarcinoma. Fifty percent patients of choriocarcinoma and 11 patients of vesicular mole were given levamisole (LVM) trial and were followed for 2 months. Absolute lymphocyte count (ALC) was significantly increased in vesicular mole after levamisole treatment but in choriocarcinoma no effect was obtained. Marked improvement of T cell rosette count was also seen in LVM treated patient of both vesicular mole (p < 0.001) and choriocarcinoma. Cutaneous DTH response to 2:4 DNCB in vesicular mole was also increased after LVM. Before treatment only 31.25% patients had strong cutaneous response but after treatment 53.35% patients had strong response, while cases of choriocarcinoma were unaffected. LVM also raised all the serum immunoglobulins (IgG, IgM, IgA) in both vesicular mole and choriocarcinoma. Hence, levamisole therapy was found to have a beneficial effect on both cellular and humoral immunity in the lesions of trophoblasts.
A Khanna, and
K N Ojha, and
R M Gupta
January 1994,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
A Khanna, and
K N Ojha, and
R M Gupta
January 1991,
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
A Khanna, and
K N Ojha, and
R M Gupta
July 1993,
Clinical pharmacy,
A Khanna, and
K N Ojha, and
R M Gupta
January 1979,
Reumatologia,
A Khanna, and
K N Ojha, and
R M Gupta
May 2000,
Immunology today,
A Khanna, and
K N Ojha, and
R M Gupta
January 1980,
Postepy higieny i medycyny doswiadczalnej,
A Khanna, and
K N Ojha, and
R M Gupta
November 1989,
Lakartidningen,
A Khanna, and
K N Ojha, and
R M Gupta
May 2005,
Pharmacotherapy,
A Khanna, and
K N Ojha, and
R M Gupta
April 1991,
Klinicheskaia meditsina,
A Khanna, and
K N Ojha, and
R M Gupta
September 2013,
Acta veterinaria Hungarica,
